In vitro antiplasmodial activity of marine sponge *Clathria vulpina* extract against chloroquine sensitive *Plasmodium falciparum*

Sundaram Prasanna Kumar, Sundaram Ravikumar *

School of Marine Sciences, Department of Oceanography and Coastal Area Studies, Alagappa university, Thondi campus, Thondi-623 409, Ramanathapuram District, Tamil Nadu, India

**ABSTRACT**

**Objective:** To explore the antiplasmodial potential of marine sponge *Clathria vulpina* against chloroquine sensitive *Plasmodium falciparum*.

**Methods:** The marine sponge *C. vulpina* was collected from Thondi coast, authenticated and subjected for extraction by soaking in ethanol:water mixture (3:1 ratio). The percentage of extract was calculated. Filter sterilized extracts (100, 50, 25, 12.5, 6.25, 3.125 μg/mL) were screened for antiplasmodial activity against chloroquine sensitive *P. falciparum*. The extract was also tested for its hemolytic activity.

**Results:** The percentage yield of extract of *C. vulpina* was found to be 4.8%. The crude extract of *C. vulpina* showed excellent antiplasmodial activity (IC50=14.75 μg/mL) which was highly comparable to the positive control chloroquine (IC50=7 μg/mL). Statistical analysis reveals that the significant antiplasmodial activity (P<0.05) was observed between the concentrations and the time of exposure. The chemical injury to erythrocytes was also carried out, which showed that there were no morphological changes in erythrocytes by the ethanolic extracts of sponges after 48 h of incubation. The extract showed slight hemolytic activity which almost equal to chloroquine at 100 μg/mL concentration (1.023%).

**Conclusions:** The marine sponge *C. vulpina* can be used as a putative antiplasmodial drug after completing successful clinical trials.

**KEYWORDS**

*Clathria vulpina*, Antiplasmodial activity, Chloroquine sensitive *Plasmodium falciparum*, Sponges

---

1. Introduction

Malaria is an infectious disease caused by the genus *Plasmodium* such as *Plasmodium falciparum* (*P. falciparum*), *Plasmodium ovale*, *Plasmodium vivax* and *Plasmodium malariae*. Among them, *P. falciparum* is the parasite responsible for most severe diseases and fatal cases, which may kill over one millions of people per annum. The parasite, *P. falciparum* is genetically diverse and has multiple independent origins of mutations in genes that confer resistance to widely used antimalarial drugs like chloroquine[1]. A major breakthrough of the past decades is the discovery of artemisinin by Chinese researchers. Artemisinin combination treatments for *P. falciparum* are currently used only first line antimalarial drugs amenable to widespread use against all chloroquinone resistant malarial parasites. However, artemisinin resistant strains were recently found in Cambodia[2]. So, there is an urgent need for the new antimalarial drugs. Living organisms are recognized as a source of potential bioactive molecules...
which are commonly more effective than those obtained through the combinatorial synthetic chemistry. Hopefully, the new breakthrough in the malaria treatment will come with the development of a marine lead compound. The incredible potential of marine organisms (mostly invertebrates, such as sponges, tunicates, and soft corals) known to produce a large array of secondary metabolites can be interpreted by considering the common features of secondary metabolism in all living organisms as well as some peculiar features of the marine environment. The marine ecosystem is the biggest source for the development of new drugs against *P. falciparum*. Pharmaceutical interest in sponges was aroused in the early 1950’s by the discovery of number of unknown nucleosides, such as spongolthymidine and spongouridine in the marine sponge *Cryptotheca crypta*[3,4]. Most of the bioactive compounds from sponges consist of anti-inflammatory, antitumor, immunosuppressive (or) neurosuppressive, antiviral, antibiotics, antifouling and antimalarial properties[5]. In this connection, the present study was made an attempt to find out the antimalarial compounds from the crude extract of marine sponge *Clathria vulpina* (*C. vulpina*) collected from Thondi coast of Palk Strait region, Tamil Nadu, India.

2. Materials and methods

2.1. Collection of marine sponges

Marine sponge *C. vulpina* was collected by by-catch at Thondi (lat. 9°44′10″N, lon. 79°10′12″E) of Palk Strait region, Tamil Nadu, India, and authenticated by Dr. S. Lazarus, emeritus fellow (retired), Centre for Marine Science and Technology, Manonmaniam Sundaranar University, Rajakkamangalam, Kanyakumari district, Tamil Nadu, India. The collected samples were washed thrice with tap water and twice with distilled water to remove the adhering associated animals. A sample voucher specimen was deposited in the herbarium facility (sponsored by the Indian Council of Medical Research, New Delhi) maintained in the Department of Oceanography and Coastal Area Studies, Alagappa University, Thondi Campus, Tamil Nadu, India.

2.2. Extraction of bioactive principles

The samples were cut into pieces and kept for shade drying. After the complete removal of moisture, the samples were subjected for percolation by soaking in ethanol:water mixture (3:1 ratio). After 21 d of dark incubation, the filtrate was concentrated separately by rotary vacuum evaporator (>45 °C) and then freeze dried (~80 °C) to obtain solid residue. The percentage of extraction was calculated by using the following formula:

\[
\text{Percentage of extraction} = \frac{\text{Weight of the extract (g)}}{\text{Weight of the sponge material (g)}} \times 100
\]

The ethanolic extracts was dissolved in dimethyl sulphoxide (Hi media Laboratories Private Limited, Mumbai, India) and filtered through sterile millipore filters (mesh 0.20 μm, Sartorious Stedim Biotech GmbH, Germany). The filtrate was used for testing at different concentrations of 100, 50, 25, 12.5, 6.25 and 3.125 μg/mL[6].

2.3. Culture maintenance

The *in vitro* antiplasmodial activity of marine sponge extract was assessed against *P. falciparum* (obtained from the Jawaharlal Nehru Centre for Advanced Scientific Research, Indian Institute of Science, Bangalore, India). *P. falciparum* were cultivated in human O Rh+ red blood cells (donated by the volunteers) using RPMI 1640 medium (Hi Media Laboratories Private Limited, Mumbai, India)[7]. Hi Media Laboratories Private Limited, Mumbai, India, supplemented with O Rh+ serum (10%), 5% sodium bicarbonate and 40 μg/mL of gentamycin sulphate. Haematocrits were adjusted at 5% and parasite cultures were used when they exhibit 2% parasitaemia[8].

2.4. In vitro antiplasmodial activity

Different concentrations of filter-sterilized crude extract from *C. vulpina* (100, 50, 25, 12.5, 6.25 and 3.125 μg/mL) were incorporated in 96–well tissue culture plate containing 200 μL of *P. falciparum* culture with fresh red blood cells diluted to 2% haematocrit. Negative control was maintained with fresh red blood cells and 2% parasitized *P. falciparum* diluted to 2% haematocrit and positive control was maintained with parasitized blood culture treated with chloroquine[9]. Parasitaemia was evaluated after 48 h by giemsa stain and the average percentage suppression of parasitaemia was calculated by the following formula:

\[
\text{Average suppression of parasitaemia} = \frac{\text{Ac}-\text{At}}{\text{Ac}} \times 100
\]

Where Ac is average percentage of parasitaemia in control (%); At is average percentage of parasitaemia in test (%).

2.5. Antiplasmodial activity calculation and analysis

The antiplasmodial activity of marine sponge *C. vulpina* were expressed by the inhibitory concentrations (IC₅₀) of the drug that induced 50% reduction in parasitaemia compared to the control (100% parasitaemia). The IC₅₀ values were calculated (concentration of extract in X-axis and percentage of inhibition in Y-axis) using office XP (SDAS) software. This activity was analyzed in accordance with the
norms of antiplasmodial activity of Rasoanaivo et al.[10]. It was suggested that an extract was very active if IC₅₀<5 μg/mL, active IC₅₀<50 μg/mL, weakly active IC₅₀<100 μg/mL and inactive IC₅₀>100 μg/mL.

2.6. Chemical injury to erythrocytes

To assess any chemical injury to erythrocytes that might attributed to the extract, 200 μL of erythrocytes was incubated with 100 μg/mL of the extract at a dose equal to the highest used in the antiplasmodial assay. The conditions of the experiment were maintained as in the case of antiplasmodial assay. After 48 h of incubation, thin blood smears were stained with giemsa stain and observed for morphological changes under high-power light microscope. The morphological findings were compared with those erythrocytes that were uninfected and not exposed to extract[13].

2.7. Hemolytic activity

Hemolytic activity was evaluated as described by Andra et al. with a slight modifications[12]. Human erythrocyte suspensions were washed with phosphate buffer saline (PBS) (1.5 mmol/L KH₂PO₄, 2.7 mmol/L KCl, 8.1 mmol/L Na₂HPO₄, 135 mmol/L NaCl, pH 7.4) and then centrifuged at 7000 r/min for 10 min. After washing four times with PBS (or until the supernatant was colourless), the human erythrocytes were re-suspended and diluted to 10 times of the original volume with PBS, referred as stock erythrocyte suspension. The suspension (2% v/v) was incubated with different concentrations (3.125 to 100 μg/mL) of C. vulpina sponge extracts at 37 °C for 1 h. After the incubation period, the reaction mixture was centrifuged at 3000 r/min for 10 min to remove intact erythrocytes. The supernatant was collected and the absorbance was determined at 450 nm by using spectrophotometer (Cyber UV-1, Mecasys Co. Ltd.) using PBS as negative control and Triton X-100 as positive control. The percent hemolysis was calculated using the formula:

\[
\text{Haemolysis (\%)} = 100 - \frac{\text{OD of test}}{\text{OD of control}} \times 100
\]

3. Results

The percentage yield of extract of C. vulpina was found to be 4.8%. The extract of C. vulpina showed excellent antiplasmodial activity (IC₅₀=14.75 μg/mL) (Table 1) which was one fold higher when compare to the positive control chloroquine (IC₅₀=7 μg/mL). The uninfected erythrocytes incubated with the ethanolic extract of marine sponge C. vulpina and uninfected erythrocytes from the blank column of the 96–well plate showed no morphological differences after 48 h of incubation. The extract showed slight hemolytic activity of 1.023% at 100 μg/mL concentration (Figure 1).

| Samples       | Yield of extract (%) | Suppression of parasitaemia (%) at 48 h |
|---------------|----------------------|----------------------------------------|
| C. vulpina    | 4.8%                 | 78.12 71.87 62.50 53.12 43.75 34.37 14.75 |
| Chloroquine   | –                    | 81.25 75.00 65.62 56.25 46.87 37.50 7.00  |

Figure 1. Hemolytic activity of crude extract of marine sponge C. vulpina.

4. Discussion

The rich diversity of bioactive compounds from sponges have provided molecules that interfere with the pathogenesis of diseases at many different points, which increase the chance of developing selective drugs against specific targets. Marine sponges have provided many examples of novel secondary metabolites that possess varied chemical status and potent antimalarial activity[5]. Marine sponges belonging to the genus Ircinia are known to be a very rich source of terpenoids, several of which have shown a wide variety of biological activities. The variabilins from terpenoids which were polyprenyl – hydroquinones, had analgesic and anti-inflammatory properties[13]. Among the halogenated alkaloids, bromoalkaloids form the most widely distributed group of natural compounds, which are predominantly found in marine eukaryotes like sponges[14]. Polycyclotylenenic alcohols, including (35,145)– petrocortyre A, purified from the marine sponge Petrosia sp., which possess the cytotoxic activity against a small panel of human solid tumor cell liner by inhibiting DNA replication[15]. The sponge Ircinia vulpina has also shown to possess antiviral, central nervous system stimulatory and antialgal properties[6]. Aplysina cavernicola, a much studied sponge which produces aeroplysinin and aethionin and other dibromo and dichlorotyrosine derivatives, found to have antibiotic activity against Bacillus subtilis and Proteus vulgaris[13]. An ethanolic extract...
of Haliclona virdis showed a significant hypoglycemic effect lasting for more than 8 h after single oral doses of 200 or 500 mg/kg to normal mice[17]. Considering these significances, present investigation has been made an attempt to evaluate the antimalarial activity of marine sponge C. vulpina against chloroquine-sensitive P. falciparum. The extract of the C. vulpina exhibited excellent antimalarial activity with the IC_{50} value of 14.75 μg/mL. And the extract showed a slight haemolytic activity of 1.0% at the concentration of 100 μg/mL and decreased significantly in lower concentrations. Song et al. reported that the saponins of Panax notoginseng exhibited the haemolytic activity of 11.6% and 3.6% at 500 mg/L and 250 mg/L concentration respectively[18]. The IC_{50} value of C. vulpina extract showed below 50 μg/mL concentration in the present investigation. According to Rasaonainvo et al., the extract which shows the in vitro antimalarial activity by <50 μg/mL is active[19]. According to the above said point, the extract of C. vulpina is active and can be used as a potential active antimalarial drug in future. The mechanism of action might be due to the inhibition of P. falciparum merozoites invasion into the erythrocytes or disruption of P. falciparum rosettes[19-21]. Ravikumar et al. reported that the bark extract from the mangrove plant of Avicennia marina exhibited minimum concentration of inhibitory activity of IC_{50} 49.63 μg/mL[22]. When compared with the above report, C. vulpina extract is more potent against the chloroquine sensitive P. falciparum. The antimalarial activities of sea weeds[23], sponge associated bacteriaill[24], terrestrial medicinal plants[25], coastal medicinal plants[8], traditional medicinal plants[26] have been reported and found to have good antimalarial activity against P. falciparum. It is reported that the endophytic fungi from Thai medicinal plants collected from forest region of Thailand, found to have excellent antimalarial activity with the IC_{50} value of 1.6–8.0 μg/mL[9]. Fattorusso et al. reported that the cyclooxygenase compounds obtained from the sponge Plakortis simplex showed a good antimalarial activity against chloroquine sensitive P. falciparum with IC_{50} 26.81 to 1263.52 nmol/L[19]. It is also reported that the marine sponge C. vulpina associated bacteria have a potent antimalarial activity of IC_{50} 20.73 μg/ml[27]. Ravikumar et al. reported that the South Indian medicinal plant Azadirachta indica (bark extract) showed a good antimalarial activity (IC_{50} 29.77 μg/mL)[28]. These findings could encourage the development of new antimalarial drugs from the marine natural products. It is concluded from the present findings that the sponge C. vulpina collected from the Thondi coast, Palk Strait region, Tamil Nadu, possesses a significant suppressive effect on in vitro cultures of chloroquine sensitive P. falciparum, which could be used as a potential antimalarial drug after completing successful clinical trials.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgements

The authors are thankful to the authorities of Alagappa University for providing required facilities. This work was financially supported by Indian Council of Medical Research, New Delhi.

Comments

Background

Malaria is an infectious disease caused by the genus Plasmodium. Among them, P. falciparum is the parasite responsible for most severe diseases and fatal cases, which may kill over one millions of people per annum. Authors have highlighted the literature report about the incredible potential of marine organisms (mostly invertebrates, such as sponges, tunicates, and soft corals) known to produce a large array of secondary metabolites. Authors selected sponge as a source material for screening antimalarial activity. Most of the bioactive compounds from sponges were used for various bioassay such as anti-inflammatory, antitumor, immune-suppressive (or) neuro-suppressive, antiviral, antibiotics, antifouling and antimalarial properties.

Research frontiers

Studies are being performed in order to screen the antimalarial activity from the crude extract of sponge C. vulpina. Marine sponges have provided many examples of novel secondary metabolites that possess varied chemical status and potent antimalarial activity.

Related reports

Authors have mentioned many related article to support this research. Compared with other extract of various sources, the extract of C. vulpina exhibited excellent antimalarial activity with less IC_{50} value of 14.75 μg/mL.

Innovations & breakthroughs

When compared with the mentioned report in this research, C. vulpina extract is more potent against the chloroquine sensitive P. falciparum with less IC_{50} value.

Applications

The study has showed C. vulpina extract is more potent against the chloroquine sensitive P. falciparum. The IC_{50} value of C. vulpina extract showed below 50 μg/mL concentration in the present investigation, so C. vulpina extract can be used as a potential active antimalarial drug in future.


Peer review

This is a good study in which the authors mentioned about the sponge *C. vulpina* possesses a significant suppressive effect on *in vitro* cultures of chloroquine sensitive *P. falciparum*. The results are interesting that *P. falciparum* could be used as a potential antimalarial drug.

References

[1] Shujatullah F, Khan HM, Khatoo A, Khan PA, Ashfaq M. *In vitro* chloroquine resistance in *Plasmodium falciparum* isolates from tertiary care hospital. *Malar Res Treat* 2012; 2012. doi: 10.1155/2012/538481

[2] Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, Dondorp AM, et al. The last man standing is the most resistant: eliminating artemisinin–resistant malaria in Cambodia. *Malar J* 2009; 8(3), doi: 10.1186/1475-2875-8-31.

[3] Jain R. Marine organism: potential source for drug discovery; 2008. [Online] Available from: http://www.currentscience.ac.in/Downloads/article_id_094_03_0292_0292_0.pdf [Accessed on 27th August, 2013]

[4] Dias D, Urban S, Roessner U. A historical overview of natural products in drug discovery metabol. *Metabolites* 2012; 2: 303–336.

[5] Fattorusso E, Taglialetela-Scafati O. Marine antimalarials. *Mar Drugs* 2009; 7(2): 130–152.

[6] Inbaneson SJ, Ravikumar S. *In vitro* antiplasmodial activity of marine sponge *Stylissa carteri* associated bacteria against *Plasmodium falciparum*. *Asian Pac J Trop Med* 2012; 5(5): 370–374.

[7] Ribas–Mundó M. DNA replication patterns of normal human leukocyte cultures: time sequence of DNA synthesis in relation to the H3–thymidine incorporation over the nucleolus. *Blood* 1966; 28: 891–900.

[8] Inbaneson SJ, Ravikumar S, Suganthi P. *In vitro* antimalarial effect of coastal medicinal plants along Palk Strait against *Plasmodium falciparum*. *Asian Pac J Trop Med* 2012; 5(5): 364–367.

[9] Prabavathy D, Nachiyar CV. Study on the antimicrobial activity of Aspergillus sp. isolated from Justicia adathoda. *Indian J Sci Tech* 2012; 5(9): 3317–3320.

[10] Rasoumai P, Wright CW, Willcox ML, Gilbert B. Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. *Malar J* 2011; 10(Suppl 1): S4.

[11] Stangeland T, Wangensteen H, Katuura E, Lye K, Paulsen B. Antioxidant and anti–plasmodial activity of extracts of three Ugandan medicinal plants. *J Med Plants Res* 2010; 4(18): 1916–1923.

[12] Andrä J, Jakovkina I, Grötzing J, Hecht O, Krasnosdembskaya AD, Goldmann T, et al. Structure and mode of action of the antimicrobial peptide arecin. *Biochem J* 2008; 410: 113–122.

[13] Supriya SJ, Yogesh SC. Marine: the ultimate source of bioactives and drug metabolites. *Int J Res Ayu Pharm* 2010; 1(1): 55–62.

[14] Jin H, Zhang P, Bijian K, Ren S, Wan S, Alaoui–Jamali MA, et al. Total synthesis and biological activity of marine alkaloid eudistomin Y1–Y7 and their analogues. *Mar Drugs* 2013; 11(5): 1427–1439.

[15] Lee YJ, Yoo SJ, Kang JS, Yun J, Shin HJ, Lee JS, et al. Cytotoxic petrosiacetylenes from the marine sponge *Petrosia* sp. *Lipids* 2013; 48(1): 87–91.

[16] Mohamed NM, Rao V, Hamann MT, Kelly M, Hill RT. Monitoring bacterial diversity of the marine sponge *Ircinia strobilina* upon transfer into aquaculture. *Appl Environ Microbiol* 2008; 74(13): 4133–4143.

[17] Shaaban M, Abd–Alla HI, Hassan AZ, Aly HF, Ghani M. Chemical characterization, antioxidant and inhibitory effects of some marine sponges against carbohydrate metabolizing enzymes. *Org Medi Chem Lett* 2012; 2(1): 30.

[18] Son H, Xu S. Adjuvant activities of saponins from traditional Chinese medicinal herbs. *Vaccine* 2009; 27(36): 4883–4890.

[19] Grassauer A, Weinmuellner R, Meier C, Pretsch A, Priesch–Grassauer E, Unger H. Iota–Carrageenan is a potent inhibitor of rhino virus infection. *Virol J* 2008; 5: 107.

[20] Leitgeb AM, Blomqvist K, Cho-Ngwa F, Samje M, Nde P, Titanji V, et al. Low anticoagulant heparin disrupts *Plasmodium falciparum* rosettes in fresh clinical isolates. *Am J Trop Med Hyg* 2011; 84(3): 390–396.

[21] Rowe A, Berendt AR, Marsh K, Newbold CI. *Plasmadium falciparum*: a family of sulphated glycoconjugates disrupts erythrocyte rosettes. *Exp Parasitol* 1994; 79: 506–516.

[22] Ravikumar S, Inbaneson SJ, Suganthi P, Venkatesan M, Ramu A. Mangrove plants as a source of lead compounds for the development of new antimalarial drugs from South East coast of India. *Parasitol Res* 2011; 108(6): 1405–1410.

[23] Ravikumar S, Inbaneson SJ, Suganthi P, Gokulakrishnan R, Venkatesan M. *In vitro* antimalarial activity of ethanolic extracts of seaweed macroalgae against *Plasmodium falciparum*. *Parasitol Res* 2011; 108: 1411–1416.

[24] Inbaneson SJ, Ravikumar S. *In vitro* antimalarial activity of bacterium *RAUTHB* 14 associated with marine sponge *Haliclona* grant against *Plasmodium falciparum*. *Parasitol Res* 2012; 110: 2255–2262.

[25] Ravikumar S, Inbaneson SJ, Suganthi P. *In vitro* antimalarial activity of chosen terrestrial medicinal plants against *Plasmodium falciparum*. *Asian Pac J Trop Biomed* 2012; 2(Suppl 1): S252–S256.

[26] Inbaneson SJ, Ravikumar S, Suganthi P. *In vitro* antimalarial activity of ethanolic extracts of Traditional medicinal plant Ocimum species against *Plasmodium falciparum*. *Asian Pac J Trop Med* 2012; 5(2): 103–106.

[27] Inbaneson SJ, Ravikumar S, Suganthi P. *In vitro* antimalarial activity of Clathria vulpina associated bacteria against *Plasmodium falciparum*. *Asian Pacific J Trop Dis* 2012; 2(4): 319–323.

[28] Ravikumar S, Inbaneson SJ, Suganthi P. *In vitro* antimalarial activity of ethanolic extracts of South Indian medicinal plants against *Plasmodium falciparum*. *Asian Pacific J Trop Dis* 2012; 2(3): 180–183.